Cargando…

Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer

Tumor necrosis factor (TNF) family members participate in the body’s antitumor immunity response and influence tumor prognosis and treatment response. However, little is known about the roles of TNF family members in small cell lung cancer (SCLC). Therefore, we conducted the first comprehensive inve...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhihui, Wu, Peng, Zhang, Chaoqi, Luo, Yuejun, Zhang, Guochao, Zeng, Qingpeng, Wang, Lide, Yang, Zhaoyang, Sun, Nan, He, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637339/
https://www.ncbi.nlm.nih.gov/pubmed/34867972
http://dx.doi.org/10.3389/fimmu.2021.745769
_version_ 1784608722520113152
author Zhang, Zhihui
Wu, Peng
Zhang, Chaoqi
Luo, Yuejun
Zhang, Guochao
Zeng, Qingpeng
Wang, Lide
Yang, Zhaoyang
Sun, Nan
He, Jie
author_facet Zhang, Zhihui
Wu, Peng
Zhang, Chaoqi
Luo, Yuejun
Zhang, Guochao
Zeng, Qingpeng
Wang, Lide
Yang, Zhaoyang
Sun, Nan
He, Jie
author_sort Zhang, Zhihui
collection PubMed
description Tumor necrosis factor (TNF) family members participate in the body’s antitumor immunity response and influence tumor prognosis and treatment response. However, little is known about the roles of TNF family members in small cell lung cancer (SCLC). Therefore, we conducted the first comprehensive investigation of TNF family members in patients with SCLC, with the goal of using them to predict prognosis and chemotherapy benefit. Abnormal genetic alterations and expression of TNF family members were found to be widespread in SCLC patients. Using LASSO Cox regression analysis, we constructed a TNF family-based signature that separated SCLC patients in the training set (n=77) into high- and low-risk groups with distinct survival and chemotherapy benefit, and the signature was well-validated in the validation set (n=137) by RT-qPCR. Importantly, the signature exhibited superior predictive performance and was identified as a novel independent prognostic factor. Additionally, different immune phenotypes were found between the low-risk and high-risk groups, and high-risk patients had higher CMTM6 expression, suggesting that these patients could benefit from therapeutic methods targeting CMTM6. We constructed the first clinically applicable TNF family-based signature for predicting prognosis and chemotherapy benefit for patients with SCLC. The findings reported here provide a new method for predicting the prognosis of SCLC patients and optimizing clinical management.
format Online
Article
Text
id pubmed-8637339
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86373392021-12-03 Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer Zhang, Zhihui Wu, Peng Zhang, Chaoqi Luo, Yuejun Zhang, Guochao Zeng, Qingpeng Wang, Lide Yang, Zhaoyang Sun, Nan He, Jie Front Immunol Immunology Tumor necrosis factor (TNF) family members participate in the body’s antitumor immunity response and influence tumor prognosis and treatment response. However, little is known about the roles of TNF family members in small cell lung cancer (SCLC). Therefore, we conducted the first comprehensive investigation of TNF family members in patients with SCLC, with the goal of using them to predict prognosis and chemotherapy benefit. Abnormal genetic alterations and expression of TNF family members were found to be widespread in SCLC patients. Using LASSO Cox regression analysis, we constructed a TNF family-based signature that separated SCLC patients in the training set (n=77) into high- and low-risk groups with distinct survival and chemotherapy benefit, and the signature was well-validated in the validation set (n=137) by RT-qPCR. Importantly, the signature exhibited superior predictive performance and was identified as a novel independent prognostic factor. Additionally, different immune phenotypes were found between the low-risk and high-risk groups, and high-risk patients had higher CMTM6 expression, suggesting that these patients could benefit from therapeutic methods targeting CMTM6. We constructed the first clinically applicable TNF family-based signature for predicting prognosis and chemotherapy benefit for patients with SCLC. The findings reported here provide a new method for predicting the prognosis of SCLC patients and optimizing clinical management. Frontiers Media S.A. 2021-11-18 /pmc/articles/PMC8637339/ /pubmed/34867972 http://dx.doi.org/10.3389/fimmu.2021.745769 Text en Copyright © 2021 Zhang, Wu, Zhang, Luo, Zhang, Zeng, Wang, Yang, Sun and He https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zhang, Zhihui
Wu, Peng
Zhang, Chaoqi
Luo, Yuejun
Zhang, Guochao
Zeng, Qingpeng
Wang, Lide
Yang, Zhaoyang
Sun, Nan
He, Jie
Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer
title Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer
title_full Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer
title_fullStr Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer
title_full_unstemmed Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer
title_short Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer
title_sort tumor necrosis factor family member profile predicts prognosis and adjuvant chemotherapy benefit for patients with small-cell lung cancer
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637339/
https://www.ncbi.nlm.nih.gov/pubmed/34867972
http://dx.doi.org/10.3389/fimmu.2021.745769
work_keys_str_mv AT zhangzhihui tumornecrosisfactorfamilymemberprofilepredictsprognosisandadjuvantchemotherapybenefitforpatientswithsmallcelllungcancer
AT wupeng tumornecrosisfactorfamilymemberprofilepredictsprognosisandadjuvantchemotherapybenefitforpatientswithsmallcelllungcancer
AT zhangchaoqi tumornecrosisfactorfamilymemberprofilepredictsprognosisandadjuvantchemotherapybenefitforpatientswithsmallcelllungcancer
AT luoyuejun tumornecrosisfactorfamilymemberprofilepredictsprognosisandadjuvantchemotherapybenefitforpatientswithsmallcelllungcancer
AT zhangguochao tumornecrosisfactorfamilymemberprofilepredictsprognosisandadjuvantchemotherapybenefitforpatientswithsmallcelllungcancer
AT zengqingpeng tumornecrosisfactorfamilymemberprofilepredictsprognosisandadjuvantchemotherapybenefitforpatientswithsmallcelllungcancer
AT wanglide tumornecrosisfactorfamilymemberprofilepredictsprognosisandadjuvantchemotherapybenefitforpatientswithsmallcelllungcancer
AT yangzhaoyang tumornecrosisfactorfamilymemberprofilepredictsprognosisandadjuvantchemotherapybenefitforpatientswithsmallcelllungcancer
AT sunnan tumornecrosisfactorfamilymemberprofilepredictsprognosisandadjuvantchemotherapybenefitforpatientswithsmallcelllungcancer
AT hejie tumornecrosisfactorfamilymemberprofilepredictsprognosisandadjuvantchemotherapybenefitforpatientswithsmallcelllungcancer